Profile data is unavailable for this security.
About the company
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
- Revenue in USD (TTM)40.93m
- Net income in USD-16.25m
- Incorporated2013
- Employees46.00
- LocationPieris Pharmaceuticals Inc225 Franklin Street, 26Th FloorBOSTON 02110United StatesUSA
- Phone+1 (857) 246-8998
- Fax+49 (8161) 141-1444
- Websitehttps://www.pieris.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organovo Holdings Inc | 242.00k | -19.09m | 12.77m | 15.00 | -- | 1.56 | -- | 52.78 | -2.17 | -2.17 | 0.0275 | 0.6283 | 0.0143 | -- | 4.44 | 12,100.00 | -112.40 | -51.24 | -123.59 | -54.90 | -- | -- | -7,886.36 | -1,269.78 | -- | -- | 0.00 | -- | -75.33 | -39.60 | -50.76 | -- | 5.99 | -- |
| Shineco Inc | 5.62m | -14.34m | 12.89m | 87.00 | -- | 0.3582 | -- | 2.29 | -3.98 | -2.32 | 1.36 | 5.58 | 0.0664 | 0.48 | 1.45 | 64,633.68 | -19.79 | -12.77 | -38.28 | -16.84 | 12.77 | 25.88 | -298.09 | -102.06 | 0.4842 | -8.14 | 0.3908 | -- | -- | -58.35 | -33.86 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 16.00m | 2.28m | 12.94m | 12.00 | -- | 0.3709 | 5.57 | 0.809 | -1.60 | -1.60 | 1.21 | 1.33 | 0.5427 | -- | 8.64 | 1,333,333.00 | 9.52 | -70.52 | 10.17 | -81.86 | -- | -- | 17.55 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Nexgel Inc | 4.74m | -3.20m | 12.95m | 19.00 | -- | 2.71 | -- | 2.74 | -0.5535 | -0.5535 | 0.8208 | 0.7688 | 0.4428 | 3.24 | 8.46 | 249,263.20 | -30.72 | -44.61 | -39.92 | -56.19 | 20.14 | 5.02 | -69.38 | -180.98 | 1.41 | -- | 0.1819 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Actavia Life Sciences Inc | 0.00 | -406.65k | 13.04m | 1.00 | -- | -- | -- | -- | -0.0005 | -0.0005 | 0.00 | -0.0028 | 0.00 | -- | -- | 0.00 | -805.97 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -5.63 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Dominari Holdings Inc | 3.41m | -24.56m | 13.12m | 26.00 | -- | 0.2752 | -- | 3.85 | -4.64 | -4.64 | 0.6305 | 8.03 | 0.0539 | -- | 0.8023 | 131,000.00 | -38.88 | -26.82 | -39.93 | -27.45 | -- | -- | -721.11 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Inhibikase Therapeutics Inc | 195.98k | -19.20m | 13.28m | 8.00 | -- | 1.76 | -- | 67.75 | -3.38 | -3.38 | 0.034 | 1.05 | 0.01 | -- | 6.08 | 24,497.50 | -97.88 | -66.49 | -118.76 | -85.55 | -- | -- | -9,797.30 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Cell MedX Corp | 70.00 | -96.91k | 13.38m | 0.00 | -- | -- | -- | 191,080.50 | -0.0029 | -0.0029 | 0.00 | -0.0024 | 0.0015 | -- | -- | -- | -202.28 | -792.55 | -- | -- | -685.71 | -- | -138,442.90 | -3,681.84 | -- | -3.17 | -- | -- | -54.53 | -- | 29.01 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 40.93m | -16.25m | 13.40m | 46.00 | -- | 0.5715 | -- | 0.3274 | -12.74 | -12.74 | 34.05 | 17.76 | 0.7324 | -- | 28.25 | 889,717.40 | -29.09 | -28.41 | -52.98 | -39.69 | -- | -- | -39.71 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Check Cap Ltd | 0.00 | -17.57m | 13.42m | 85.00 | -- | 0.5669 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Imunon Inc | 0.00 | -18.85m | 13.54m | 33.00 | -- | 1.59 | -- | -- | -2.02 | -2.02 | 0.00 | 0.9041 | 0.00 | -- | -- | 0.00 | -66.82 | -50.18 | -91.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Akari Therapeutics PLC (ADR) | -100.00bn | -100.00bn | 13.58m | 9.00 | -- | -- | -- | -- | -- | -- | -- | -0.4449 | -- | -- | -- | -- | -- | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Senti Biosciences Inc | 1.28m | -86.11m | 13.73m | 48.00 | -- | 0.2445 | -- | 10.77 | -1.93 | -1.44 | 0.0285 | 1.23 | 0.0097 | -- | 2.94 | 26,562.50 | -65.33 | -- | -71.42 | -- | -- | -- | -6,753.80 | -- | -- | -- | 0.0018 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.25m | 13.93m | 16.00 | -- | 3.22 | -- | -- | -2.37 | -2.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -84.50 | -- | -107.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 14.01m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
Data as of Jun 06 2024. Currency figures normalised to Pieris Pharmaceuticals Inc's reporting currency: US Dollar USD
36.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 15 May 2024 | 257.62k | 20.83% |
| Lynx1 Capital Management LPas of 31 Mar 2024 | 109.74k | 8.87% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 17.87k | 1.45% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 12.94k | 1.05% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 12.03k | 0.97% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 11.07k | 0.90% |
| Citadel Advisors LLCas of 31 Mar 2024 | 9.84k | 0.80% |
| Geode Capital Management LLCas of 31 Mar 2024 | 9.66k | 0.78% |
| CM Management LLCas of 31 Mar 2024 | 7.19k | 0.58% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 3.05k | 0.25% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
